Southlake, Texas--(Newsfile Corp. - October 18, 2022) - Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ:HSCS) (NASDAQ:HSCSW) ("HeartSciences" or the "Company"), a medical technology company focused on saving lives by making an ECG (also known as an EKG) a far more valuable screening tool through the use of AI, today announced that Andrew Simpson, Chairman and Chief Executive Officer of HeartSciences, will be presenting at the 15^th annual LD Micro Main Event being held at the Luxe Sunset Boulevard Hotel in Los Angeles, California.

Presentation details are as follows:

Event:	LD Micro Main Event XV
Date:	Wednesday, October 26, 2022
Time:	3:30 PM PT/ 6:30 PM ET

About the LD Micro Main Event XV

The 2022 LD Micro Main Event XV will be held at the Luxe Sunset Boulevard Hotel in Los Angeles from October 25th to the 27th. The festivities will run from 7:30 AM PT - 5:30 PM PT on the 25th and 26th, with a half day on Thursday the 27th. This three-day, investor conference is expected to feature around 200+ companies, presenting in half-hour increments, as well as private meetings.

For more info, please contact Mr. Dean "The Dream" Summers. Dean@ldmicro.com

About LD Micro

LD Micro aims to be the most crucial resource in the micro-cap world. Whether it is the index, comprehensive data, or hosting the most significant events on an annual basis, LD's sole mission is to serve as an invaluable asset for all those interested in finding the next generation of great companies.

http://www.ldmicro.com

About HeartSciences

Heart Test Laboratories, Inc. d/b/a HeartSciences is medical technology company focused on applying innovative AI-based technology to an ECG (also known as an EKG) to expand and improve an ECG's clinical usefulness. The Company's objective is to improve healthcare by making an ECG a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. HeartSciences' first product candidate for FDA clearance, the MyoVista wavECG, or the MyoVista, is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction which has traditionally only been available through the use of cardiac imaging. The MyoVista also provides conventional ECG information in the same test. The business model, which involves the use of the MyoVista device and consumables for each test, is expected to be "razor-razorblade" as the electrodes used with the MyoVista are proprietary to HeartSciences, and new electrodes are required for every test performed.

For more information, please visit: https://www.heartsciences.com. Twitter: @HeartSciences

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are made under the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and are relating to the Company's future financial and operating performance. All statements, other than statements of historical facts, included herein are "forward-looking statements" including, among other things, statements about HeartSciences' beliefs and expectations. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company's control. The expectations reflected in these forward-looking statements involve significant assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Potential risks and uncertainties include, but are not limited to, risks discussed in HeartSciences' filings with the U.S. Securities and Exchange Commission at www.sec.gov. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

For investor and media inquiries, please contact:

Investor Relations:
Crescendo Communications, LLC
Phone: (212) 671-1021
Email: HSCS@crescendo-ir.com

Company:
Gene Gephart
Phone: +1-737-414-9213 (US)
Email: investorrelations@heartsciences.com

Corporate Logo

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/140902